Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Novavax (NasdaqGS:NVAX) with a Sell recommendation.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Published in the Journal of the American Medical Association (JAMA), the letter says that the dismissal of the advisors and ...